Lilly Mubadala Bio deal adds a GLP 1 packaging stage at a KEZAD site in Abu Dhabi

Abu Dhabi is getting a packaging role in the supply chain for the best selling incretin drugs. The Lilly Mubadala Bio agreement, signed on 20 October 2026, covers localised packaging and logistics for GLP-1 medicines from Eli Lilly at a 125,000 square metre site in KEZAD. Neither side gave a value or a start date. The work will begin in phases, and each step depends on technical, quality and regulatory requirements, so this is a plan to add a packaging stage, not a new peptide plant.

What the two companies signed in Abu Dhabi

The deal was announced at the Abu Dhabi Future Health Summit by Hamad Almarzooqi, group deputy chief executive of Mubadala Bio, and Nabil Daoud, who runs the Intercontinental Hub for Lilly. The signing was witnessed by Dr Fatima Al Kaabi, director general of the Emirates Drug Establishment, the national regulator, along with the chairman of Mubadala Bio and the head of Lilly Gulf. According to the Abu Dhabi Media Office release, the partnership will run from a KEZAD site with packaging and warehousing buildings. The release says the site also supports the wider pharmaceutical logistics and contract manufacturing work Mubadala Bio offers to outside clients from the United Arab Emirates.

The products named in coverage of the deal are Mounjaro and Foundayo. Mounjaro is tirzepatide, a peptide that acts on the GIP and GLP-1 receptors, and the UAE was one of its early launch markets in August 2022. Foundayo is orforglipron, a once daily pill that the Emirates Drug Establishment approved for chronic weight management in April, making the UAE the second country to register it. Orforglipron is a small molecule, not a peptide, so only half of the named pair belongs to peptide chemistry. The agreement text does not name a third product, and the companies did not say which pack formats, pens or tablet packs, will be handled first at the Abu Dhabi site.

Packaging or contract manufacturing

The headline of the government release speaks of pharmaceutical contract manufacturing, but its body describes packaging and logistics, and the difference matters for supply. Packaging can mean secondary work such as labelling, cartons and serialisation for local markets, or it can mean primary steps closer to the drug itself. The release does not say which. Almarzooqi went further in remarks reported by The National, saying the drugs "will be contract-manufactured here in the UAE and distributed around the world." That is a statement by one partner, made on stage. Lilly's own quoted executives spoke of capabilities and partnership, and none of them said that any Lilly active ingredient or finished pen would be produced in the emirate under this agreement.

Lilly's own quoted executives spoke of capabilities and partnership, and none of them said that any Lilly active ingredient or finished pen would be produced in the emirate under this agreement.

For readers tracking capacity, the safest reading is the narrow one. The tirzepatide ingredient still comes from Lilly's chemistry plants, such as the site we covered in Lebanon, Indiana, and pens are filled at sterile sites the company owns or contracts. A packaging and warehousing hub in Abu Dhabi adds a last step for regional supply. It can shorten lead times to Gulf markets, allow local language packs and hold stock nearer patients. It does not add peptide output. If Mubadala Bio later takes on filling or formulation, that would need its own inspection and approvals, and neither company has announced such a step or a date for it.

Why Lilly wants a Gulf hub

Lilly already runs a large and widening factory network, from new US sites to its injectables plant in Alzey, Germany, and to purchases of finished plants such as the one in Pleasant Prairie. The Lilly Mubadala Bio agreement is different in kind, because Lilly is not buying or building anything there. It is using a partner's site for a downstream step. Edgardo Hernandez, who heads Lilly Manufacturing Operations, said in the release that the Mubadala Bio team "shares our urgency to meeting patient demand", which ties the deal to demand for incretin drugs rather than to cost. The release did not say which countries beyond the UAE the hub will serve.

The Gulf side has its own reasons. The National reported that most pharmaceutical products in the UAE are imported and that Mubadala Bio, founded in May 2025, has a five year plan to change that and already runs four manufacturing plants in the country. The same report said the company kept essential medicines flowing this year during shipping disruption in the Strait of Hormuz, partly by building raw material stocks and using other routes and ports. A local packaging stage fits that drug security goal. For Lilly it means a regional partner with state backing and a direct line to the national regulator, which witnessed the signing and handles product registration.

What the deal leaves open

Several basic facts are missing. No contract value has been disclosed, and the companies gave no date for the first phase, no volume of packs and no staffing figure. The release also does not say how many of the 125,000 square metres are given over to Lilly work or whether the space is shared with other clients of Mubadala Bio. Each phase is subject to technical, quality and regulatory requirements, which suggests inspections and site approvals still lie ahead. That makes the Lilly Mubadala Bio arrangement an announced plan rather than a running line, and we have recorded its build status as announced until either company reports that packing has actually started at the KEZAD site.

There is also a question about how far the hub reaches. Almarzooqi spoke of distribution around the world, but the government release talks about the region and global industry partners without naming export markets or approval routes. Packs made for Europe or the United States would need those regulators to accept the site, and no such filing has been reported. Against the larger capacity moves in this sector, such as the Catalent fill and finish plants that passed to Novo Nordisk, this is a modest step. It still matters for the Gulf, where demand for weight loss medicines is high and supply has relied mostly on imports.

Conclusion

The Lilly Mubadala Bio agreement gives Lilly a packaging and warehousing stage for GLP-1 medicines at a 125,000 square metre KEZAD site in Abu Dhabi. The work will start in phases with no disclosed value or date. Mounjaro is a peptide, Foundayo is not, and nothing announced adds peptide ingredient or pen filling capacity. The next facts to watch are the first phase date and any regulator approval of the site.